entertainment -WSS

entertainment

author：entertainment 2025-09-27 10:01:09 - browse：311

Former MIT and Whitehead Institute star biologist David Sabatini, who lost his positions after he was accused of violating sexual harassment policies in 2021, is resuming his science career, taking a post at a Czech research institute in Prague.

Sabatini, of Cambridge, confirmed in a phone call from Prague that he has accepted a position as a “senior group leader” at the Institute of Organic Chemistry and Biochemistry, known as IOCB Prague. Sabatini said he will be recruiting staff and running a laboratory in the Czech Republic capital to investigate scientific questions in the areas of cell growth and metabolism, similar to his past research in Cambridge.

“I’m very grateful to be given the opportunity to do science again,” said Sabatini, who began working at the institute last month.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Cancer researcher Catriona Jamieson is sending tumors into space

focus

WSS

After traumatic brain injury, life support decisions can use more time

Key Senate committee drafts bipartisan bill to stem drug shortages

Medicare inequities exacerbate Puerto Rico’s health disparities

Q&A: Jennifer Adair on making gene therapy available globally

Alabama hospital puts IVF treatments on hold

Antivenom research: Lessons from HIV applied in search for universal antidote

hotspot

entertainment

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Obesity drugs seen as possible treatment for liver disease MASH

Alkermes shareholders re

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Cancer drug shortages should be causing more outrage

The Harvard botanist who searched for psychedelics in the Amazon

Duchenne breakthrough therapy leaves behind pioneering families

Medicare inequities exacerbate Puerto Rico’s health disparities

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

focus

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

With competition flaring, obesity drug hits goal in liver disease study

FTC falls short on scrutinizing hospital mergers, study says

Cue Health's Covid

Dogs on Prozac: What pet anti

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

focus

focus

focus

entertainment